The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
CD20 is a non-glycosylated phosphoprotein expressed on the surface of pre-B cells, mature B lymphocytes, and most B-cell malignancies, but absent from haematopoietic stem cells and plasma cells. Its precise physiological function remains incompletely understood, though it likely functions as a calcium channel and is involved in B-cell activation and proliferation. The restricted expression pattern — present on the target B-cell populations but absent from the precursors (protecting haematopoietic reconstitution) and terminally differentiated plasma cells (preserving existing antibody repertoire) — makes CD20 an ideal therapeutic target for both B-cell malignancies and autoimmune diseases driven by B-lymphocyte pathology.
Anti-CD20 monoclonal antibodies are classified as type I (rituximab, ofatumumab) or type II (obinutuzumab) based on their CD20 binding epitope and conformational changes induced upon binding. Type I antibodies translocate CD20 into lipid rafts, facilitating complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Type II antibodies such as obinutuzumab are glycoengineered to enhance FcgammaRIII binding and ADCC, and uniquely elicit direct non-apoptotic cell death, while showing reduced CDC. In CLL, obinutuzumab plus chlorambucil demonstrated superior PFS versus rituximab plus chlorambucil in the CLL11 trial, establishing a clinical correlate of these mechanistic differences.
In multiple sclerosis, CNS B-cell and plasmablast involvement in both relapsing and progressive disease has established CD20 depletion as a highly effective treatment strategy. Ocrelizumab (anti-CD20, IV, 6-monthly) demonstrated superiority over interferon-beta-1a in relapsing MS and became the first therapy approved for primary progressive MS in any regulatory jurisdiction. Ofatumumab (anti-CD20, SC, monthly) provides self-administration convenience with comparable efficacy. Ublituximab offers rapid B-cell depletion with a differentiated infusion schedule. Sustained B-cell depletion and the optimal timing of monitoring (B-cell repopulation, immunoglobulin levels) are important considerations for long-term management.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
Clinically actionable insights for treatment selection and sequencing
CD20 is a non-glycosylated phosphoprotein expressed on the surface of pre-B cells, mature B lymphocytes, and most B-cell malignancies, but absent from haematopoietic stem cells and plasma cells.
Its precise physiological function remains incompletely understood, though it likely functions as a calcium channel and is involved in B-cell activation and proliferation.
The restricted expression pattern — present on the target B-cell populations but absent from the precursors (protecting haematopoietic reconstitution) and terminally differentiated plasma cells (preserving existing antibody repertoire) — makes CD20 an ideal therapeutic target for both B-cell malignancies and autoimmune diseases driven by B-lymphocyte pathology.
Anti-CD20 monoclonal antibodies are classified as type I (rituximab, ofatumumab) or type II (obinutuzumab) based on their CD20 binding epitope and conformational changes induced upon binding.
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Haematology Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →